Akari Therapeutics, Plc (AKTX) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-03-30
How it makes money
It currently earns no revenue and relies on equity offerings to fund its development.
The company is pre-revenue. It develops antibody-drug conjugates (ADCs), which are therapies that combine targeting antibodies with toxic payloads to attack cancer cells.
Future profit will depend on obtaining marketing authorization for its candidates and the ability of its PH1 payload to outperform existing treatments.
What protects it: the moat
It claims a competitive advantage by using a novel payload mechanism different from most competitors.
Management asserts that its PH1 payload targets RNA splicing by modulating the spliceosome, which allows it to kill cancer cells and activate the immune system.
This is presented as a differentiator because the vast majority of other ADCs in development rely on only two standard payload classes.
What growth costs
It must invest in clinical trials and manufacturing to move candidates toward commercialization.
Growth requires funding for IND-enabling studies, Phase 1 trials, and eventual commercial manufacturing.
Maintenance costs include general and administrative expenses and the costs of obtaining and enforcing patents.
What could damage it
A failure to raise capital would force the termination of development, preventing any future revenue.
Because it has no revenue and only $5.2 million in cash, it depends entirely on external financing.
If it cannot secure more funds on acceptable terms, it must stop developing its product candidates, which would permanently impair its ability to ever reach the market.
About Akari Therapeutics, Plc
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.